Ipriflavone

Drug #1159

Ipriflavone is a synthetic isoflavonoid that inhibits reabsorption of bone. Ipriflavone is given by mouth and is available for the treatment of osteoporosis.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Isoflavanoid .

It is classified in Bone Metabolism pharmacological group.

Molecular Weight: 280.3 · Solubility in Water: null · Solubility in Alcohol: null · Non-proprietary name: Ipriflavone.

Pharmacokinetics

Distribution: Ipriflavone has a volume of distribution is . plasma protein binding is .

Elimination: it is metabolised via , plasma half-life is , renal excretion is .

Indications

Ipriflavone is primarily indicated in conditions like Hyperparathyroidism, Osteoporosis, Paget's disease of bone.

Contraindications

Ipriflavone is contraindicated in conditions like GI ulceration.

Dosage

Ipriflavone's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
500	500	—
900 mg	900 mg	—		Paget''s disease weak bones due to lidney disease.
200 mg	200 mg	Every 8h	PO	Postmenopavsal osteoporosis.
Paediatric Dosage (20kg)
0 – 0	—	—		Not recommended in this age group
Neonatal Dosage (3kg)
0 – 0	—	—		Not recommended in this age group

Drug Interactions

6 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Ipriflavone in overdosage may give rise to further complications which include Eelvated hepatic enzymes , Hyperbilirubinemia.

Ipriflavone produces potentially life-threatening effects which include Lymphocytopenia. Careful monitoring is needed with proper medical management.

Ipriflavone is known to cause more or less tolerable side effects which are usually transient. These include Dizziness, GI disturbance, VertigoX.

Warnings / Precautions

Ipriflavone should be cautiously administered to patients with serious hepatic or renal lesions and hematological disturbances. There in no information about the safety in children. If administered to patient under therapy with coumarin-anticoagulants ipriflavone causes an increase in their activity, therefore a monitor of the coagulation parameters and if necessary, an adjustment of the anticoagulant drug dosage are advisable.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Tabs

200 mg

Storage Conditions

Ipriflavone should be stored .

Drug Classification

1.18.14 — Drugs affecting bone metabolism

Manufacturers

Manufacturers of Ipriflavone in Pakistan:

Chiesi Raazee